| Document |
Document Title |
|
WO/2023/040106A1 |
Disclosed in the present invention is a preparation method for an acetamide compound by means of green visible-light catalysis. In the method, LED lamps are used as light sources to provide energy, and economically available aromatic ami...
|
|
WO/2023/044171A1 |
The disclosure provides compounds with nitrile warheads and their use in treating medical diseases or disorders, such as viral infections. Pharmaceutical compositions and methods of making various compounds with nitrile warheads are prov...
|
|
WO/2023/043816A1 |
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein)...
|
|
WO/2023/020519A9 |
A Compound of formula (I) or (II), a stereoisomer thereof, an atropisomer, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of the stereoisomer, a pharmaceutically acceptable salt of the atropisomer, a prodr...
|
|
WO/2023/039671A1 |
Synergistic nanomedicine delivering topoisomerase I toxin (SN-38) and inhibitors of polynucleotide kinase 3'-phosphatase (PNKP) for enhanced treatment of colorectal cancer
|
|
WO/2023/040513A1 |
The present invention relates to a crystal form of a compound I and a preparation method therefor, a pharmaceutical composition containing the crystal form, and the use of the crystal form in the preparation of a drug for treating relate...
|
|
WO/2023/042170A1 |
This invention relates to a field of pharmaceuticals, in particular to desidustat particles having specific particle size distribution and pharmaceutical compositions thereof.
|
|
WO/2023/040914A1 |
Disclosed are a method for treating cancer with a CDK4/6 inhibitor and a corresponding pharmaceutical use. The CDK4/6 inhibitor is 5-fluoro-4-(7'-fluoro-2'-methylspiro[cyclopentane-1, 3'-indole]-5'-yl)-nitrogen-(5-(1-methylpiperidin-4-yl...
|
|
WO/2023/040989A1 |
Provided are compounds useful as KRAS G12C inhibitors, as well as pharmaceutical compositions comprising these compounds and methods of treatment by administration of these compounds or the pharmaceutical compositions.
|
|
WO/2023/039573A1 |
This present disclosure provides compounds which are useful in treating medical disorders. More particularly, compounds are provided for targeted degradation of TAF1 which are useful in the treatment of cancers.
|
|
WO/2023/039275A1 |
The present invention relates to certain substituted AHR agonist compounds, to pharmaceutical compositions comprising the compounds and to methods of using the compounds to treat immune-mediated diseases.
|
|
WO/2023/035223A1 |
Provided in the present invention are a pharmaceutical composition containing a therapeutically effective amount of Furmonertinib or a pharmaceutically acceptable salt thereof and optionally a pharmaceutically acceptable carrier, and the...
|
|
WO/2023/035082A1 |
The disclosure relates to a method of detecting the presence of tumor infiltrating Fc receptor-expressing immune cells in a mammalian subject afflicted with a cancer or detecting the presence of one or more site(s) of inflammation charac...
|
|
WO/2023/038330A1 |
The present invention relates to a heterocyclic compound represented by chemical formula 1, an organic light-emitting device comprising same, and a composition for an organic substance layer.
|
|
WO/2023/039505A1 |
The present disclosure relates compounds of Formula (0): and pharmaceutically acceptable salts and stereoisomers thereof. The present disclosure also relates to methods of preparing the compounds, compositions comprising the compounds, a...
|
|
WO/2023/036289A1 |
Disclosed are a compound of formula (I) having ENPP1 inhibitory activity, a pharmaceutical composition thereof and use thereof. The compound of formula (I) can be used for preventing or treating the diseases or disorders mediated by the ...
|
|
WO/2023/036976A1 |
The present invention relates to a heterocyclic compound of formula (1), which is substituted by at least one cyano group, as well as compositions and devices comprising these compounds, especially organic electroluminescent devices comp...
|
|
WO/2023/036934A1 |
The present invention relates to cyclopropyl-(hetero)aryl substituted ethylsulphonyl-pyridine derivatives of formula (I),wherein the variables are as defined in the description and in the claims, which can be used as antiparasitic agents...
|
|
WO/2023/039089A1 |
The invention relates to a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof, compositions comprising the same and methods of preparing and using the same.
|
|
WO/2023/035667A1 |
Disclosed is a low-cost preparation method for palbociclib. The method comprises: taking 4-(6-aminopyridin-3-yl)piperazine-1-carboxylic acid tert-butyl ester as an initial raw material, taking large-steric-hindrance alkali as an acid-bin...
|
|
WO/2023/038341A1 |
The present specification relates to: a heterocyclic compound represented by chemical formula 1; and an organic light-emitting device comprising same.
|
|
WO/2023/037253A1 |
The present invention discloses an isoxazoline compound of formula (I), Formula (I) wherein, R1, R3, Cy, ring-Q, A, D, p and q are as defined in the detailed description. The present invention further discloses methods for preparation of...
|
|
WO/2023/036285A1 |
A heteroaromatic compound and an application thereof. Specifically, provided is a compound as represented by formula I, or an optical isomer, raceme, solvate, hydrate, pharmaceutically-acceptable salt, or prodrug thereof. The compound ha...
|
|
WO/2023/039278A1 |
The present invention relates to certain substituted AHR agonist compounds, to pharmaceutical compositions comprising the compounds and to methods of using the compounds to treat immune-mediated diseases.
|
|
WO/2023/036350A1 |
The present invention relates to compounds of general formula (I) for use as complexing agents. The invention further relates to the coordination compounds thereof, peptide conjugates, method of their preparation and use thereof.
|
|
WO/2023/029812A1 |
Provided in the embodiments of the present invention are a matrine crystal, a pharmaceutical composition and the uses thereof, so as to improve the solubility of matrine and a drug using matrine as an active ingredient and to shorten the...
|
|
WO/2023/031335A1 |
The present invention relates to a process for the preparation of an optically pure (+) or (-) enantiomer of an iminium salt having the formula (I), aid process comprising the following steps: • a) a reduction step of an iminium salt h...
|
|
WO/2023/034812A1 |
The present disclosure features compounds and related compositions that, inter alia, modulate nucleic acid splicing, e.g., splicing of a pre-mRNA, as well as methods of use thereof.
|
|
WO/2023/030215A1 |
The present invention relates to a substituted pyridopyrimidone derivative, and a preparation method therefor and the use of a pharmaceutical composition containing same in medicines. Specifically, the present invention relates to a subs...
|
|
WO/2023/032306A1 |
The present invention addresses the problem of providing: light-emitting nanoparticles for enabling a high-luminous particle technique for bioimaging and also enabling a high-sensitivity imaging; and a light-emitting labeling material fo...
|
|
WO/2023/032940A1 |
The present invention provides a compound which has PDHK inhibitory activity and which is useful for treating or preventing diabetes (type 1 diabetes, type 2 diabetes, etc.), insulin resistance syndrome, metabolic syndrome, hyperglycemia...
|
|
WO/2023/034364A1 |
The present disclosure encompasses solid state forms of Vericiguat, in embodiments crystalline polymorphs of Vericiguat, processes for preparation thereof, and pharmaceutical compositions thereof.
|
|
WO/2023/031775A1 |
The present invention relates to a pharmaceutical composition for preventing or treating Charcot-Marie-Tooth disease associated with a peripheral nervous system, comprising a compound represented by formula I, optical isomers thereof or ...
|
|
WO/2023/034811A1 |
The present disclosure features compounds and related compositions that, inter alia, modulate nucleic acid splicing, e.g., splicing of a pre-mRNA, as well as methods of use thereof.
|
|
WO/2023/030478A1 |
The present invention relates to a pyridolactam derivative, a preparation method therefor, and a medical use of a pharmaceutical composition comprising the derivative. Specifically, the present invention relates to a substituted pyridola...
|
|
WO/2023/029638A1 |
The present invention relates to the field of biological medicines, and relates to an N,N-diphenylamino-modified β-carboline indolium salt, a preparation method and the use. The β-carboline indolium salt has a structure as represented ...
|
|
WO/2023/034644A2 |
The present disclosure is directed to methods of treating or ameliorating various conditions by the administration of a BCN057, BCN077 and analogs. BCN057, BCN077 and analogs can be used to modulate PD-1 and treat various ailments in whi...
|
|
WO/2023/030517A1 |
Provided are novel compounds useful as KRAS G12C inhibitors, as well as pharmaceutical compositions comprising these compounds and methods of treatment by administration of these compounds or the pharmaceutical compositions.
|
|
WO/2023/030495A1 |
Disclosed relates to compounds that inhibit KRAS. In particular, disclosed relates to compounds that inhibit the activity of KRAS G12D,pharmaceutical compositions co-mprising the compounds and methods of use there for.
|
|
WO/2023/034290A1 |
Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or d...
|
|
WO/2023/034946A1 |
The invention relates to heterocyclic compounds of formulae (I) and (II), pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods...
|
|
WO/2023/034827A1 |
The present disclosure features compounds and related compositions that, inter alia, modulate nucleic acid splicing, e.g., splicing of a pre-mRNA, as well as methods of use thereof.
|
|
WO/2023/034833A1 |
The present disclosure features compounds (I) and related compositions that, inter alia, modulate nucleic acid splicing, e.g., splicing of a pre-mRNA, as well as methods of use thereof.
|
|
WO/2023/029380A1 |
The present invention relates to a novel aryl ether substituted heterocyclic compound having GLP1R agonist activity. Specifically, disclosed are a compound as a GLP1R agonist represented by formula (I), or a pharmaceutically acceptable s...
|
|
WO/2023/029814A1 |
Provided in the embodiments of the present invention are a matrine crystal, a pharmaceutical composition, a therapeutic agent for soil-borne diseases and the uses thereof, which can reduce the solubility of matrine and a drug using matri...
|
|
WO/2023/025307A1 |
Provided are substituted tricyclic compounds as PARP inhibitors and the use thereof. The compounds are represented by Formula (I) as below, wherein, the ring Z, Z1, Z2, A1, A2, A3, L and Cy are defined herein. The compounds of Formula (I...
|
|
WO/2023/025159A1 |
An IRAK4 degradation agent as represented by structural formula PTM-L-ULM (I), and a preparation method therefor and the use thereof. The provided compound can effectively inhibit and/or degrade IRAK4 kinase protein in a cell and inhibit...
|
|
WO/2023/027995A1 |
A compound represented by Formula 1 according to the present disclosure, when used in combination with an anticancer drug, may significantly improve the anticancer effect of the anticancer drug, and may induce the same anticancer effect ...
|
|
WO/2023/025116A1 |
The present invention relates to a heterocyclic derivative, a preparation method therefor and the use thereof in medicine. Specifically, the present invention relates to a heterocyclic derivative represented by general formula (I), a pre...
|
|
WO/2023/025244A1 |
The present invention provides an application of an SARM1 enzyme activity inhibitor in the treatment of neurodegenerative diseases or neurological diseases or conditions. The present invention particularly provides a compound of formula ...
|
